<--- Back to Details
First PageDocument Content
Pharmacology / Research / Medical terms / Health Canada / Health in Canada / Adverse effect / Postmarketing surveillance / Medicine / Health / Clinical research
Date: 2012-11-30 03:45:54
Pharmacology
Research
Medical terms
Health Canada
Health in Canada
Adverse effect
Postmarketing surveillance
Medicine
Health
Clinical research

Add to Reading List

Source URL: www.osteoporosis.ca

Download Document from Source Website

File Size: 33,42 KB

Share Document on Facebook

Similar Documents

Pharmaceuticals policy / Health / Medical research / Pharmacovigilance / European Medicines Agency / EudraLex / European Directive on Traditional Herbal Medicinal Products / Postmarketing surveillance / Adverse effect / Qualified Person Responsible For Pharmacovigilance / EudraVigilance

COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 10 December 2008 SECVolume I

DocID: 1qH6O - View Document

Medicine / Clinical research / Pharmaceuticals policy / Medical technology / Medical equipment / Postmarketing surveillance / Research / Medical device / Administrative guidance

IMDRF Presentation - WHO update

DocID: 1q40h - View Document

Medical equipment / Clinical research / Medical technology / Pharmaceuticals policy / Clinical trials / Postmarketing surveillance / Medical device / Global Harmonization Task Force / Interactive television / Validation

IMDRF Presentation - Update on WHO work

DocID: 1oBkV - View Document

Health / Medicine / Pharmaceuticals policy / Drug safety / Pharmacy / Pharmacovigilance / EudraLex / Qualified Person Responsible For Pharmacovigilance / Postmarketing surveillance / Pharmacology / Pharmaceutical sciences / Clinical research

Microsoft Word - Volume IX ENdoc

DocID: 1g2y9 - View Document

Pharmaceutical industry / Health / Pharmaceuticals policy / Clinical research / Pharmacovigilance / Good manufacturing practice / Postmarketing surveillance / Pharmaceutical sciences / Pharmacy / Pharmacology

Kyrgyzstan Assessment of Pharmaceutical Data Disclosure Disclosure Status of Pharmaceutical Sector Data Part of Component 1 of the MeTA Baseline Assessments Kyrgyz Republic

DocID: 1fUrF - View Document